Enhancing neural markers of attention in children with ADHD using a digital therapeutic.

Autor: Gallen CL; Department of Neurology, University of California, California, San Francisco, United States of America.; Neuroscape Center, University of California, California, San Francisco, United States of America., Anguera JA; Department of Neurology, University of California, California, San Francisco, United States of America.; Neuroscape Center, University of California, California, San Francisco, United States of America.; Department of Psychiatry, University of California, California, San Francisco, United States of America., Gerdes MR; Department of Neurodevelopmental Medicine, Cortica Healthcare, San Rafael, CA, United States of America., Simon AJ; Department of Neurology, University of California, California, San Francisco, United States of America.; Neuroscape Center, University of California, California, San Francisco, United States of America., Cañadas E; Akili Interactive Labs, Boston, MA, United States of America., Marco EJ; Department of Neurodevelopmental Medicine, Cortica Healthcare, San Rafael, CA, United States of America.; Department of Radiology, University of California, California, San Francisco, United States of America.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2021 Dec 31; Vol. 16 (12), pp. e0261981. Date of Electronic Publication: 2021 Dec 31 (Print Publication: 2021).
DOI: 10.1371/journal.pone.0261981
Abstrakt: Attention deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition characterized by diminished attentional control. Critically, these difficulties are related to negative consequences in real-life functioning both during development and into adulthood. There is now growing evidence that modulating the underlying neural circuits related to attention can improve behavior and brain function in children with ADHD. We have previously shown that game-based digital therapeutics targeting a key neural marker of attention-midline frontal theta (MFT)-yield positive effects on attentional control in several populations. However, the effects of such digital therapeutics in children with ADHD and no other comorbidities has not been yet examined. To address this gap, we assessed a sample of 25 children with ADHD (8-12 years old) on neural, behavioral, and clinical metrics of attention before and after a 4-week at-home intervention on an iPad targeting MFT circuitry. We found that children showed enhancements on a neural measure of attention (MFT power), as well as on objective behavioral measures of attention and parent reports of clinical ADHD symptoms. Importantly, we observed relationships between the neural and behavioral cognitive improvements, demonstrating that those children who showed the largest intervention-related neural gains were also those that improved the most on the behavioral tasks indexing attention. These findings provide support for using targeted, digital therapeutics to enhance multiple features of attentional control in children with ADHD. Study registration: ClinicalTrials.gov registry (NCT03844269) https://clinicaltrials.gov/ct2/show/NCT03844269.
Competing Interests: JAA was paid as a consultant by Cortica to assist with study development, EEG equipment setup, neural and behavioral analysis, and manuscript preparation. EJM, MG, BC are employees of Cortica. EC is employed by Akili Interactive Labs, may own stock options, and is a patent holder (WO/2018/027080) for Processor Implemented Systems and Methods for Measuring Cognitive Abilities. Funding for this study was sponsored by Akili Interactive Labs.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje